GlassScriptPhysician profile
Katie G Spear
NPI 1548253974
$361,037.67
in general payments reported to CMS, 2019-2025
15 companies · $46K in 2025
The $46K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139K · 2020: $17K · 2021: $31K · 2022: $22K · 2023: $71K · 2024: $36K · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $102K · Travel and Lodging: $26K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $7,047.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $102,284.45 |
| Travel and Lodging | $26,075.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,280.00 |
| Food and Beverage | $7,047.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $290,042.73 | 2019-2025 | Total30, Dailies Total1, Precision 1 |
| Glaukos Corporation | $57,362.27 | 2022-2025 | Kxl System (Not Refurbished), Ce-Marked Kxla System, Kxl System |
| Alcon Research LLC | $10,246.51 | 2019-2022 | |
| Allergan, INC. | $1,863.37 | 2019-2021 | |
| Oyster Point Pharma, INC. | $393.81 | 2022-2024 | Tyrvaya |
| Sight Sciences, INC. | $370.69 | 2019-2022 | |
| Abbvie INC. | $272.56 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $121.44 | 2020 | |
| Bausch & Lomb Americas INC. | $93.50 | 2024 | Miebo, Xiidra |
| Tearlab Corp | $82.61 | 2022 | |
| Lombart Brothers, INC. | $63.08 | 2020 | |
| Dompe US, INC. | $41.67 | 2025 | Oxervate |
| Carl Zeiss Meditec, INC. | $35.45 | 2021 | |
| Optos, INC. | $25.90 | 2022 | |
| Osmotica Pharmaceutical Corp. | $22.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Spear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.